POSC162 Cost Effectiveness Analysis of Nivolumab Plus Ipilimumab Therapy in Patients with Advanced Non-Small Cell Lung Cancer in Japan

Abstract

Authors

X Mo K Moriwaki K Morimoto K Shimozuma

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×